

10/27/2025 16:04:09

Page 1 of 1

Interim Report

NAME: [REDACTED]  
 [REDACTED] AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR# [REDACTED] DR: [REDACTED]  
 Order Priority: Routine  
 Test Name: HEMOGLCBINA1C (83036)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: MESINA, CANDY  
 Order Number: 3

Final

CHEMISTRY

Collected: 10/27/2025 12:04

<u>Test</u>	<u>Result</u>	<u>REFERENCE RANGE</u>
HGA1C	5.5	4.0-5.0 %
Hgb C, E and S do not interfere with this assay. Other Hgb variants may interfere.		
MEAN PLASMA GLUC	111	<=126 MG/DL

Collected Date: 10/27/2025 12:04:00 Release Date: 10/27/2025 15:45  
 MEDICAL DIR: [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

Interim Report

NAME: [REDACTED]  
 AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR#: [REDACTED] DR: [REDACTED]  
 Order Priority: Routine  
 Test Name: CBC W/AUTO DIFF (85025)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: RUEDAS, RAFAEL  
 Order Number: 1

Final

HEMATOLOGY

Collected: 10/27/2025 12:04

Test	Result	REFERENCE RANGE
CBC WITH AUTO DIFFERENTIAL		
WBC	6.60	4.50-11.50 T/UL
RBC, BLD	5.09	4.60-6.00 M/UL
HGB	16.4	13.0-18.0 G/DL
HCT	47.6	40.0-54.0 %
MCV	93.9	80.0-94.0 FL
MCH	32.2	27.0-34.0 PG
MCHC	34.3	32.0-36.0 G/DL
RDW	13.6	11.5-14.5 %
PLT	186	150-450 T/UL
NEUT%	59.6	40.0-74.0 %
LYMPHS%, CBC	32.4	15.2-43.3 %
MONOS Percent	5.4	5.5-13.7 %
EOS%, CBC	2.0	0.4-6.7 %
BASOS%	0.6	0.2-1.5 %
ABS NEUT	3.9	1.4-6.5 K/uL
ABS LYMPHS	2.1	1.0-3.2 K/uL
ABS MONOS	0.4	0.3-1.1 K/uL
ABS EOS	0.10	0.00-0.40 K/uL
ABS BASOS	0.00	0.00-0.10 K/uL
MANUAL DIFF INDIC	NO	

Collected By: [REDACTED]  
 MEDICAL DIRECTOR [REDACTED]

Collected Date: 10/27/2025 12:04:00

Release Date: 10/27/2025 13:16

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

Interim Report

NAME: [REDACTED]  
 VI [REDACTED] AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR# [REDACTED] DR: [REDACTED]  
 Order Priority: Routine  
 Test Name: COMPREHENSIVE METABOLIC PNL (80053)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: CASTRO DELGADO, ESTEFANI  
 Order Number: 2

Final

CHEMISTRY

Collected: 10/27/2025 12:04

Test	Result	REFERENCE RANGE
GLU	88	74-106 MG/DL
BUN	16	6-20 MG/DL
CREA SERUM	1.05	0.67-1.17 MG/DL
TP	7.1	6.4-8.3 G/DL
ALB	4.5	3.5-5.2 G/DL
GLOB	2.6	2.0-4.0 G/DL
A/G	1.7	1.0-3.0
CA	9.6	8.6-10.0 MG/DL
AST w/P5P	25	<=50 U/L
ALT w/P5P	43	<=50 U/L
ALP	63	40-129 U/L
NA	137	136-145 MMOLA
K	4.2	3.4-5.1 MMOLA
CL	98	98-107 MMOLA
CO2	28	22-29 MEQA
eGFR	95	>=60 mL/min/1.73 m2

An estimated GFR is included with creatinine results for patients 16 years and older.

The eGFR calculation was changed to the CKD-EPI 2021 race-free equation on 09-27-2023.

ANION GAP	15	11-19 MMOLA
TBILI, Gen 3	0.6	0.0-1.2 MG/DL

Collected By: [REDACTED]  
 MEDICAL DIRECTOR [REDACTED]

Collected Date: 10/27/2025 12:04:00

Release Date: 10/27/2025 14:15

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

10/27/2025 15:42:44

Page 1 of 1

Interim Report

NAME: [REDACTED]

Vs: [REDACTED]

AGE: 35Y

SEX: Male

DOB: 03/29/1990

Unknown Bed

ADMITTED: 10/27/2025 11:47

TECH ID: CASTRO DELGADO, ESTEFANI

Order Priority: Routine

Test Name: LIPID PANEL (80061)

Order Number: 5

Final

CHEMISTRY

Collected: 10/27/2025 12:04

Test	Result		REFERENCE RANGE
CHOL	227	H	20-200 MG/DL
TRIG	154	H	0-150 MG/DL
HDL	39	L	40-120 MG/DL
LDL	166	H	0-100 MG/DL
VLDL	31		10-40 MG/DL
CHOL/HDL	5.8		

Collected [REDACTED]

Collected Date: 10/27/2025 12:04:00

Release Date: 10/27/2025 14:15

MEDICAL DIRECTOR [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

Interim Report

NAME: [REDACTED]  
 [REDACTED] AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR#: [REDACTED] DR: [REDACTED]  
 Order Priority: Routine  
 Test Name: T3, FREE (84481)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: RUEDAS, RAFAEL  
 [REDACTED]  
 Order Number : 12

Final



Collected: 10/27/2025 12:04

<u>Test</u>	<u>Result</u>	<u>REFERENCE RANGE</u>
T3 FREE	3.1	2.4-4.2 pg/ml

Collected By: [REDACTED] Collected Date: 10/27/2025 12:04:00 Release Date: 10/27/2025 14:03  
 MEDICAL DIRECTOR [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

10/27/2025 15:36:28

Page 1 of 1

Interim Report

NAME: [REDACTED]

Unknown Bed

[REDACTED]

AGE: 35Y

SEX: Male

DOB: 03/29/1990

ADMITTED: 10/27/2025 11:47

MR#: [REDACTED]

TECH ID: RUEDAS, RAFAEL

Order Priority: Routine

Order Number: 11

Test Name: THYROID PANEL

Final

CHEMISTRY

Collected: 10/27/2025 12:04

<u>Test</u>	<u>Result</u>	<u>REFERENCE RANGE</u>
TSH	1.720	0.270-4.200 mIU/ML
T4 FREE	1.20	0.93-1.70 NG/DL

Collected By: [REDACTED]

Collected Date: 10/27/2025 12:04:00

Release Date: 10/27/2025 14:03

MEDICAL DIRECTOR: [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

Interim Report

NAME: [REDACTED]  
 [REDACTED] AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR#: [REDACTED] DR: [REDACTED]  
 Order Priority: Routine  
 Test Name: VITAMIN D 25-OH, TOTAL (82306)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: MESINA, CANDY  
 [REDACTED]  
 Order Number: 13

Final

CHEMISTRY

Collected: 10/27/2025 12:04

Test	Result	REFERENCE RANGE
VITAMIN D REFERENCE INTERVALS (HEALTH BASED):		
VITAMIN D DEFICIENCY	<= 20 ng/mL	
VITAMIN D INSUFFICIENCY	<= 30	
PREFERRED LEVEL	> 30	
POSSIBLE TOXICITY	> 150	
VIT D 25-OH TOTAL	50	30-100 ng/mL

Collected By: [REDACTED] Collected Date: 10/27/2025 12:04:00 Release Date: 10/27/2025 14:33  
 MEDICAL DIRECTOR: [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.



10/29/2025 23:56:58

Page 1 of 1

Interim Report

NAME: ██████████  
 V ██████████ AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR# ██████████ ██████████  
 Order Priority: Routine  
 Test Name: LUTEINIZING HORMONE (A-70093) (83002)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: MANAGER, INTERFACE  
 Order Number: 7

Final

REFERENCE LAB

LU LUTEINIZING HORMONE (A-70093) (83002)

Collected 10/27/2025 12:04 REFERENCE RANGE

LH <0.3 L 17-8.8 IU/L

REFERENCE INTERVAL: Luteinizing Hormone

Access complete set of age- and/or gender-specific  
 reference intervals for this test in the ARUP Laboratory  
 Test Directory (aruplab.com).  
 Performed By: ARUP Laboratories  
 500 Chipeta Way  
 Salt Lake City, UT 84108  
 Laboratory Director: Jonathan R. Genzen, MD, PhD  
 CLIA Number: 46D0523979

Collected By: ██████████ Collected Date: 10/27/2025 12:04:00 Release Date: 10/29/2025 23:58  
 MEDICAL DIRECTOR ██████████

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.





10/30/2025 02:34:43

Page 2 of 2

Interim Report

NAME: [REDACTED]  
 Visit ID: [REDACTED] AGE: 35Y SEX: Male DOB: 03/29/1990  
 MR#: [REDACTED]  
 Order Priority: Routine  
 Test Name: TESTOST, FREE & TOT, MEN (A-70109) (84403)

Unknown Bed  
 ADMITTED: 10/27/2025 11:47  
 TECH ID: MANAGER, INTERFACE  
 Order Number: 10

Final

REFERENCE LAB

Collected 12:04 REFERENCE RANGE

(SHBG). Testosterone immunoassays are both imprecise and inaccurate at low testosterone concentrations, such as those found in children and cisgender females. For these individuals, testing by mass spectrometry is recommended; refer to Testosterone, Free (Adult Females, Children, or Individuals on Testosterone-Suppressing Hormone Therapy) (ARUP test code 0081059).

For individuals on testosterone hormone therapy, refer to cisgender male reference intervals. No reference intervals have been established for males younger than 14 years or for cisgender females. For a complete set of all established reference intervals, refer to [lit.aruplab.com/Tests/Pub/0070109](http://lit.aruplab.com/Tests/Pub/0070109).

TESTOST, % FREE See Note 1.8-2.9 %

The percent Free Testosterone result is greater than 2.9 percent.

Performed By: ARUP Laboratories  
 500 Chipeta Way  
 Salt Lake City, UT 84108  
 Laboratory Director: Jonathan R. Genzen, MD, PhD  
 CLIA Number: 46D0523979

Collected By: [REDACTED] Collected Date 10/27/2025 12:04:00 Release Date: 10/30/2025 02:34  
 MEDICAL DIR [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.



10/30/2025 15:31:27

Page 2 of 2

Interim Report

NAME: [REDACTED]

Visit ID: [REDACTED]

AGE: 35Y

SEX: Male

DOB: 03/29/1990

Unknown Bed

ADMITTED: 10/27/2025 11:47

TECH ID: MANAGER, INTERFACE

MR#: [REDACTED]

Order Priority: Routine

Test Name: PSA, FREE / TOT (A-80206) (84164)

Order Number: 4

Final

REFERENCE LAB

Collected

12:04

REFERENCE RANGE

In patients with total PSA concentrations of 4-10 ng/mL, the probability of finding prostate cancer on needle biopsy by age in years is:

%fPSA	50-59	60-69	70 or older
0 - 10%	49%	58%	65%
11 - 12%	27%	34%	41%
19 - 25%	16%	24%	30%
Greater than 25%	9%	12%	16%

Other factors may help determine the actual risk of prostate cancer in individual patients.

Performed By: ARUP Laboratories

500 Chipeta Way

Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

CLIA Number: 46D0523979

Collected By: [REDACTED]  
MEDICAL DIRECTOR [REDACTED]

Collected Date: 10/27/2025 12:04:00

Release Date: 10/30/2025 14:03

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.

Interim Report

NAME: [REDACTED]

Unknown Bed  
ADMITTED: 10/27/2025 11:47

Visit ID: [REDACTED] AGE: 35Y SEX: Male DOB: 03/29/1990

TECH ID: MANAGER, INTERFACE

MR#: [REDACTED]

Order Number: 6

Order Priority: Routine  
Test Name: ESTRADIOL, ULTRASENSITIVE (A-93247) (82670)

Final



ESTRADIOL, ULTRASENSITIVE (A-93247) (82670)

Collected	10/27/2025 12:04	REFERENCE RANGE
ESTRADIOL	14.9	10.0-42.0 pg/mL

REFERENCE INTERVAL: Estradiol by Mass Spec

- Pre-menopausal: Early follicular 30.0-100.0 pg/mL
  - Pre-menopausal: Late follicular 100.0-400.0 pg/mL
  - Pre-menopausal: Luteal 50.0-150.0 pg/mL
  - Post-menopausal 2.0-21.0 pg/mL
- REFERENCE INTERVAL: Estradiol by Mass Spec

For a complete set of all established reference intervals refer to [id.aruplab.com/Tests/Pub/0013247](http://id.aruplab.com/Tests/Pub/0013247).

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Performed By: ARUP Laboratories  
500 Chipeta Way  
Salt Lake City, UT 84108  
Laboratory Director: Jonathan R. Genzen, MD, PhD  
CLIA Number: 46D0523379

Collected By: [REDACTED] Collected Date: 10/27/2025 12:04:00 Release Date: 11/02/2025 20:45  
MEDICAL DIRECTOR [REDACTED]

L - LOW H - HIGH # - CRITICAL \* - SIGNIFICANT CHANGE C - CORRECTED

Confidentiality Notice: This fax, including any attachments, is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please notify the sender and destroy all copies of the fax. Thank you for your cooperation.